GlassScriptPhysician profile
Lisa B Conry
NPI 1699708685
$1,162.71
in general payments reported to CMS, 2019-2025
20 companies · $328 in 2025
The $328 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $67.71 · 2021: $82.89 · 2022: $122 · 2023: $138 · 2024: $305 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $353.79 | 2022-2025 | Azstarys |
| Sobi, INC | $179.95 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $82.34 | 2024-2025 | |
| Glaxosmithkline, LLC. | $54.85 | 2023-2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $53.20 | 2025 | Jornay Pm |
| Tris Pharma INC | $52.30 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $45.87 | 2024 | |
| Merck Sharp & Dohme LLC | $42.66 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $42.29 | 2019-2021 | |
| Neos Therapeutics, LP | $40.65 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.79 | 2022-2024 | Flumist Quadrivalent |
| Kaleo, INC. | $31.44 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $30.17 | 2025 | Relexxii |
| Biogen, INC. | $25.47 | 2024 | Spinraza |
| Supernus Pharmaceuticals, INC. | $23.46 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $17.00 | 2019 | |
| Sanofi Pasteur INC. | $15.96 | 2023 | |
| Genentech USA, INC. | $14.44 | 2019 | |
| Allegis Pharmaceuticals, LLC | $12.08 | 2023 | Spinosad |
| Glenmark Therapeutics INC. | $8.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Conry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.